• NIKTIMVO (axatilimab) approved by the Therapeutic Goods Administration (TGA) under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease[2]
  • Australia becomes the first country to obtain Marketing Authorisation for NIKTIMVO since approval by the US FDA[3]
  • Australian-led research played key role in the development of NIKTIMVO, a first-in-class novel colony stimulating factor-1 receptor (CSF-1R) blocking antibody.